Related Experiment Video
Updated: Aug 5, 2026
10:17
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
Polymorphisms in the human paraoxonase (PON1) promoter
V H Brophy1, M D Hastings, J B Clendenning
1The University of Washington, Division of Medical Genetics, Seattle, WA 98195-7360, USA.
Pharmacogenetics
|February 24, 2001
Summary
Genetic variations in the paraoxonase (PON1) gene promoter influence its expression levels. Specific polymorphisms, particularly at -909, -162, and -108, significantly impact PON1 activity, affecting its protective functions.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Paraoxonase (PON1) is an HDL-associated protein crucial for antioxidant defense and detoxification.
- Significant inter-individual variability exists in PON1 expression levels.
- Understanding genetic regulation of PON1 is vital for its therapeutic and toxicological implications.
Purpose of the Study:
- To identify genetic factors within the PON1 promoter region influencing PON1 expression levels.
- To investigate the functional impact of identified PON1 promoter polymorphisms on gene activity.
Main Methods:
- Deletion analysis of the PON1 promoter in transient transfection assays.
- Sequence analysis of PON1 promoter regions from individuals with varying PON1 expression.
- Reporter gene assays to assess the functional effects of promoter polymorphisms.
Main Results:
- Cell-type specific promoter elements for liver and kidney are located within the first 200bp upstream of the PON1 coding sequence.
- Five polymorphisms were identified in the PON1 promoter region (-108, -126, -162, -832, -909).
- Polymorphisms at -909, -162 (potential NF-I site), and -108 (potential SP1 site) each approximately doubled PON1 expression, with non-additive effects observed.
Conclusions:
- Genetic polymorphisms in the PON1 promoter, specifically at -909, -162, and -108, are key determinants of PON1 expression levels.
- These findings provide insights into the molecular basis of PON1 activity variability.
- The identified polymorphisms offer potential targets for modulating PON1 activity in health and disease contexts.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...